Recombinant Human BRAF Protein，His

BRAF (B-Raf proto-oncogene, serine/threonine kinase) is a critical component of the RAS-RAF-MEK-ERK signaling pathway, which regulates cell proliferation, differentiation, and survival. Mutations in the BRAF gene, particularly the V600E mutation, are frequently associated with various cancers, including melanoma, thyroid, and colorectal cancers, leading to aberrant activation of this pathway. This has prompted extensive research into BRAF as a therapeutic target; selective BRAF inhibitors, such as vemurafenib and dabrafenib, have been developed and are used in clinical settings for treating BRAF-mutant tumors. However, resistance to these therapies often develops, necessitating further investigation into BRAF’s structural characteristics and interactions with other proteins. Recombinant BRAF proteins, produced through genetic engineering techniques, facilitate the study of its function in cellular signaling as well as the exploration of novel inhibitors. Additionally, these recombinant proteins enable researchers to examine the effects of specific mutations on BRAF activity and drug resistance mechanisms, thereby enhancing our understanding of tumor biology and paving the way for the development of more effective treatments. Understanding BRAF’s role in cancer also extends to potential combination therapies that target multiple points in the signaling pathway, aiming to circumvent resistance and improve patient outcomes. This comprehensive approach underscores the importance of BRAF research in the field of oncology and personalized medicine.